


Make *HeartCare* part of your rejection risk assessment

HeartCare is the only test that provides a comprehensive view of rejection*

The intersection of immune activation and graft injury reveals risk stratification not seen with either test alone.¹



The HeartCare *Personalized* Risk Report

HeartCare is the only test that provides a Personalized Risk Report, combining measures of immune activation and graft injury for more precise risk assessment

**Biopsy unlikely
to reveal ACR**

**AlloMap(-),
AlloSure(-)**

1.5% risk of ACR

Seen in 49% of SHORE
HeartCare results*

Stay the course
or optimize
immunosuppression

**AlloMap(+),
AlloSure(-)**

1.9% risk of ACR

Seen in 35% of SHORE
HeartCare results

Consider CMV
infection

**AlloMap(-),
AlloSure(+)**

4.3% risk of ACR

Seen in 7% of SHORE
HeartCare results

Consider other
pathological causes

**Biopsy more likely
to reveal ACR**

**AlloMap(+),
AlloSure(+)**

9.2% risk of ACR

Seen in 9% of SHORE
HeartCare results

Take action:
Consider a biopsy

AlloMap(+) is ≥ 30 for ≥ 2 -6 months or ≥ 34 for >6 months. AlloSure(+) is $\geq 0.2\%$.

This information is provided for informational purposes only and is not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on their education, clinical expertise, current guidelines, and assessment of the patient.

This information is designed for the context of surveillance testing for ACR; For patients that are at risk of AMR or being tested in other clinical context, different guidance may apply.

ACR: acute cellular rejection; AMR: antibody-mediated rejection;
CMV: cytomegalovirus.

* HeartCare is the only test that provides measures of both immune system activation and graft injury

1. Teuteberg J, Patel S, Baran DA, et al. *J Heart Lung Transplant*. Published online November 24, 2025. doi:10.1016/j.healun.2025.11.013

2. Khush K, Hall S, Kao A, et al. *J Heart Lung Transplant*. 2024;43(9):1409-1421.

© 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.
VTS-PRO-10075-v4. Effective 04.2026.